Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.97 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.97 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.97 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.97 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.97 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.57 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.57 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluconazole SCHEMBL27658993 | 0.99 | CYP3A4 (0.95) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL3151 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL5503188 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL5597261 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL29360276 | 0.99 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27534402 | 0.97 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL20305060 | 0.97 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27971366 | 0.97 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL27514614 | 0.97 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 | |
| Fluconazole SCHEMBL28141272 | 0.97 | CYP3A4 (0.97) | CYP3A4CYP2C9CYP2C19LMNAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107935947-A | A kind of preparation method of Fluconazole crystal form III | 苏州天马药业有限公司 | 2018-04-20 | — | — | CN | claimed |
| CN-105399693-A | Fluconazole monohydrate crystal form and preparation method thereof | UNIV NINGBO | 2016-03-16 | — | — | CN | claimed |
| US-7094904-B2 | Process for preparing monohydrate and crystal modifications of fluconazole | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2006-08-22 | — | — | US | claimed |
| CN-1789270-A | Mycotic ingection-resisting fosfluconazole hydrate and preparation method thereof | XI AN XIN AN MEDICINE TECHNOLO (CN) | 2006-06-21 | — | — | CN | claimed |
| EP-1373227-B1 | PROCESS FOR PREPARING FLUCONAZOLE AND ITS CRYSTAL MODIFICATIONS | RICHTER GEDEON VEGYESZET (HU) | 2005-11-09 | — | — | EP | claimed |
| JP-2004524348-A | — | — | 2004-08-12 | — | — | JP | claimed |
| US-20040106804-A1 | Process for preparing monohydrate and crystal modifications of fluconazole | RICHTER GEDEON VEGYESZETI GYAR RT. | 2004-06-03 | — | — | US | claimed |
| EP-1373227-A1 | PROCESS FOR PREPARING FLUCONAZOLE AND ITS CRYSTAL MODIFICATIONS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-01-02 | — | — | EP | claimed |
| WO-2002076955-A1 | PROCESS FOR PREPARING FLUCONAZOLE AND ITS CRYSTAL MODIFICATIONS | RICHTER GEDEON VEGYESZÉTI GYÁR RT. (HU) | 2002-10-03 | — | — | WO | claimed |
| EP-1001947-A1 | PROCESS FOR MANUFACTURING FLUCONAZOLE | DAE WOONG PHARMACEUTICAL CO., LTD. (KR) | 2000-05-24 | — | — | EP | claimed |
| WO-1998032744-A1 | PROCESS FOR MANUFACTURING FLUCONAZOLE | DAE WOONG PHARMACEUTICAL CO., LTD. (KR) | 1998-07-30 | — | — | WO | claimed |
| CN-107935947-A | A kind of preparation method of Fluconazole crystal form III | 苏州天马药业有限公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-105399693-A | Fluconazole monohydrate crystal form and preparation method thereof | UNIV NINGBO | 2016-03-16 | — | — | CN | disclosed |
| CN-105399693-A | Fluconazole monohydrate crystal form and preparation method thereof | UNIV NINGBO | 2016-03-16 | — | — | CN | disclosed |
| CN-105399693-A | Fluconazole monohydrate crystal form and preparation method thereof | UNIV NINGBO | 2016-03-16 | — | — | CN | disclosed |
| WO-2002076955-A1 | PROCESS FOR PREPARING FLUCONAZOLE AND ITS CRYSTAL MODIFICATIONS | RICHTER GEDEON VEGYESZÉTI GYÁR RT. (HU) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002076955-A1 | PROCESS FOR PREPARING FLUCONAZOLE AND ITS CRYSTAL MODIFICATIONS | RICHTER GEDEON VEGYESZÉTI GYÁR RT. (HU) | 2002-10-03 | — | — | WO | disclosed |
| CN-1353108-A | Process for preparing fluconazole as antifungal medicine | MILITARY MEDICAL UNIV NO 2 PLA (CN) | 2002-06-12 | — | — | CN | disclosed |
| EP-1001947-A1 | PROCESS FOR MANUFACTURING FLUCONAZOLE | DAE WOONG PHARMACEUTICAL CO., LTD. (KR) | 2000-05-24 | — | — | EP | disclosed |
| WO-1998032744-A1 | PROCESS FOR MANUFACTURING FLUCONAZOLE | DAE WOONG PHARMACEUTICAL CO., LTD. (KR) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106804-A1 | Process for preparing monohydrate and crystal modifications of fluconazole | ERG28, CYP2F1, SI | CYP3A4 16/4885CYP2C9 36/4885CYP2C19 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.